Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer. 2007 Oct 11; 6:63.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Cetuximab
Dose-Response Relationship, Drug
Down-Regulation
ErbB Receptors
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
Kinetics
Lung Neoplasms
Mutation
Phosphorylation
Protein Kinase Inhibitors
Quinazolines
Receptor Protein-Tyrosine Kinases

authors with profiles

ZHEN FAN